scholarly journals The Novel PrisMax Continuous Renal Replacement Therapy System in a Multinational, Multicentre Pilot Setting

2018 ◽  
Vol 46 (3) ◽  
pp. 220-227 ◽  
Author(s):  
Marcus Broman ◽  
Max Bell ◽  
Olivier Joannes-Boyau ◽  
Claudio Ronco
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
User Satisfaction ◽  
Treatment Time ◽  
Journal Club ◽  
Raw Material ◽  
The Novel ◽  
User Friendliness ◽  
Filter Life

Background/Aims: We assessed how the novel PrisMax continuous renal replacement therapy (CRRT) system performed in a prospective international multicentre setting. We compared this device to its predecessor, the Prismaflex, with regards to multiple treatment parameters. Additionally, we performed a survey, aiming to measure user satisfaction. Methods: Data was prospectively collected from 7 intensive care units (ICU) in 6 countries. The PrisMax device data logs constituted the raw material. Clinical parameters like treatment time, filter life span, downtime, delivered dose and number and type of alarms were recorded. A user questionnaire was sent out to 3 of the participating ICUs. Results: Filter life, downtime, blood pump stops, bag changing time and number of malfunction alarms showed significantly improved values compared to the historic Prismaflex data. The survey showed high scores with regards to user friendliness. Conclusion: The PrisMax CRRT device is safe and outperformed its’ previous generation counterpart in virtually all aspects. Video Journal Club “Cappuccino with Claudio Ronco” at http://www.karger.com/?doi=489213.

Comparison of the Accuracy of the Novel PrisMax Continuous Renal Replacement Therapy System to the Classic Prismaflex System

2018 ◽  
Vol 47 (1-3) ◽  
pp. 166-170 ◽  
Author(s):  
Max Bell ◽  
Marcus Broman ◽  
Olivier Joannes-Boyau ◽  
Claudio Ronco
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Treatment Time ◽  
Raw Material ◽  
The Novel ◽  
Dose Delivery ◽  
Delivery Methods ◽  
Multicentre Setting ◽  
Delivered Dose

Background/Aims: We assessed how the novel PrisMax continuous renal replacement therapy (CRRT) system performed in an international multicentre setting. The system has multiple novel tools aiming to increase accuracy and dose delivery. Methods: Data was prospectively collected from 7 intensive care units in 6 countries. The PrisMax device data logs constituted the raw material and last generation Prismaflex data was used as comparison. Clinical parameters like treatment time, filter life span, downtime as well as prescribed and delivered dose were recorded. Results: PrisMax delivered/prescribed effluent ratios (mean ± SD) 0.92 ± 0.15 vs. Prismaflex ratios 0.85 ± 0.21, p < 0.001; delivered effluent dose (mL/kg/h) was 18.16 ± 12.93 vs. 10.95 ± 10.96, p < 0.0001; and (Kt/V) 0.76 ± 0.52 vs. 0.44 ± 0.44, p < 0.0001. Moreover, downtime was 27 minutes less for the newer device. Conclusion: The PrisMax CRRT device outperforms its predecessor with regard to dose delivery and accuracy.

scholarly journals Early mobilization on continuous renal replacement therapy is safe and may improve filter life

Critical Care ◽  
2014 ◽  
Vol 18 (4) ◽  
pp. R161 ◽  
Author(s):  
Yi Wang ◽  
Terry P Haines ◽  
Paul Ritchie ◽  
Craig Walker ◽  
Teri A Ansell ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Early Mobilization ◽  
Filter Life

scholarly journals A First Evaluation of OMNI®, A New Device for Continuous Renal Replacement Therapy

2016 ◽  
Vol 43 (1-3) ◽  
pp. 11-17 ◽  
Author(s):  
Pierre Schläpfer ◽  
Jean-Daniel Durovray ◽  
Valery Plouhinec ◽  
Cristiano Chiappa ◽  
Rinaldo Bellomo ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Interface Design ◽  
Journal Club ◽  
Total Duration ◽  
Fluid Removal ◽  
New Device

Background: Omni® (B. Braun, Germany) is a new-generation, continuous renal replacement therapy (CRRT) machine designed to improve user interface, minimize downtime and optimize renal dose delivery. It was never tested in humans. Methods: We used Omni® to provide CRRT in 10 critically ill patients. We collected therapy data, metabolic parameters and evaluated user's satisfaction with a survey. Results: CRRT was delivered using Omni® in CVVH-heparin (6 patients) and CVVHD-citrate (4 patients) modes for a total duration of 617.7 h. No adverse event was observed. The mean filter life was 22.8 (CVVH-heparin) and 33.5 (CVVHD-citrate) h. Alarms-related downtime corresponded to 5.9% of total therapy time. Delivered renal dose was 96.6% of prescribed. Satisfactory metabolic control and fluid removal were achieved. Overall, users evaluated interface, design and usability as excellent. Conclusion: CRRT in CVVH-heparin and CVVHD-citrate modes was provided using Omni® in a safe and efficient way for 10 critically ill patients. Video Journal Club ‘Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=451053.

scholarly journals How Does Continuous Renal Replacement Therapy Affect Septic Acute Kidney Injury?

2018 ◽  
Vol 46 (4) ◽  
pp. 326-331 ◽  
Author(s):  
Jingxiao Zhang ◽  
Jiakun Tian ◽  
Hongzhi Sun ◽  
Kumar Digvijay ◽  
Mauro Neri ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Renal Replacement Therapy ◽  
Water Balance ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Journal Club ◽  
Kidney Injury ◽  
Extra Energy ◽  
Septic Acute Kidney Injury ◽  
Metabolic Products

Sepsis is the leading cause of acute kidney injury (AKI) in the intensive care unit. As the most common treatment of septic AKI, it is believed that continuous renal replacement therapy (CRRT) can not only maintain the water balance and excrete the metabolic products but also regulate the inflammation and promote kidney recovery. CRRT can remove the inflammatory cytokines to regulate the metabolic adaption in kidney and restore the kidney recovery to protect the kidney in septic AKI. Second, CRRT can provide extra energy supply in septic AKI to improve the kidney energy balance in septic AKI. Third, the anticoagulant used in CRRT also regulates the inflammation in septic AKI. CRRT is not only a treatment to deal with the water balance and metabolic products, but also a method to regulate the inflammation in septic AKI. Video Journal Club ‘Cappuccino with Claudio Ronco’ at https://www.karger.com/Journal/ArticleNews/223997?​sponsor=52.

Do anti-platelet drugs improve duration of continuous renal replacement therapy? A retrospective cohort study in cardiac ICU patients

2021 ◽  
pp. 039139882110312
Author(s):  
Vivek Gupta ◽  
Naved Aslam ◽  
Shibba Takkar Chhabra ◽  
Vikas Makkar ◽  
Bishav Mohan ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
North India ◽  
Filter Life ◽  
Anti Platelet Drug ◽  
The Impact

Objective: The objective of this study was to investigate the impact of anti-platelet drug/s on duration of continuous renal replacement therapy (CRRT) in those patients where anti-coagulants were not used due to certain contraindications and in cases where patients were on anti-platelet drugs and were given anti-coagulant during CRRT. Method: This single-center, retrospective cohort study was conducted using the medical records patients treated with CRRT in the cardiac ICU of the inpatient urban facility, located in North India. Data was collected from only those patients who received CRRT for the duration of at least 12 h. Patient’s in NAC group were not on any anti-platelet/s and did not receive anti-coagulant during CRRT. AC and AP group patients received anti-coagulant alone or were already on anti-platelet/s and did not receive anti-coagulant respectively while ACAP group patients were on anti-platelet drug/s and also received anti-coagulant during CRRT. Result: Patients in AC, AP, or ACAP group showed significantly ( p < 0.001) higher CRRT filter life compared to NAC group. The median CRRT filter life was significantly higher in the ACAP group compared to AC ( p < 0.05) and AP ( p < 0.001) groups. Conclusion: This study indicates that systemic anti-platelet therapy can provide additional support in critical patients undergoing CRRT even with or without anti-coagulant therapy. However, the increase in CRRT filter life was more profound in patients who were on anti-platelet/s and also received anti-coagulant drug/s during CRRT.

Sign in / Sign up

Export Citation Format

Share Document